Corporate Learning Technology Company Attensi Announces $26m Investment From Lugard Road Capital, DX Ventures, and Viking Venture for Global Expansion
8.4.2021 10:00:00 EEST | Business Wire | Press release
Corporate Learning and Development (L&D) technology innovator Attensi is executing its plans for global expansion after raising $26m from New York-based Lugard Road Capital, DX Ventures, and existing share holder Viking Venture. The investment follows several years of rapid growth for the company, during which Attensi has recorded a 63% CAGR in annual recurring revenue and executed projects for a wide range of international blue-chip customers. The new funding will be used by Attensi to extend its presence in North America and Europe and to expand upon its leading product suite and technology platform in gamified simulations.
“Attensi solutions enable organizations to upskill their people faster, consistently, at scale, with results beyond the capabilities of traditional methods like e-learning, video, or classroom training. With gamified simulation training, we have combined the best of workplace psychology with our expertise in simulations and gamification to create a new category of training solutions. Our gamified simulations create significant real-world impact on companies’ core business metrics,” said Attensi Co-Founder and Co-CEO, Trond Aas. “This funding round enables our ambitious growth plans. With Lugard Road Capital we are bringing in a major US investor with experience of growing SaaS companies into global brands.”
With a client base that includes Daimler Mercedes Benz, Circle K, Equinor, BCG, and ASDA, Attensi uses a fusion of technology from the world of video gaming and insights from workplace psychology to train people via immersive, 3D simulations of their workplace and work processes. At the end of last year, the company announced plans to further develop its technology platform and enter new markets by the end of 2021. The fundraise from Lugard Road Capital, DX Ventures, and Viking Venture represents an acceleration of these plans.
Anne-Lise Waal, CTO and Co-CEO at Attensi said: “This is exciting news for everyone at Attensi. With the Attensi Technology Platform users across the globe can create high-end gamified solutions with our powerful no-code toolset. This investment will be instrumental in further expanding our cloud native SaaS platform and product suite. The Attensi Technology Platform will equip companies across all sectors to deliver on the challenge of continuous development and upskilling of their workforce. Our current plans for organizational expansion will see our staff count grow rapidly from the current level of 120 to well over 200.”
Doug Friedman, partner at Lugard Road Capital, said: “We could not be more excited to be investing in the Attensi team as they work to forever change and improve corporate learning and development through their Attensi solutions.”
Duncan McIntyre, Managing Director at DX Ventures, said: “Learning and development opportunities are becoming a decisive competitive factor to improve performance, attract and retain talent. We are thrilled to support Attensi to achieve its mission to make corporate training more effective and engaging.”
Eivind Bergsmyr, partner at Viking Venture, commented: “It’s been exciting to see the rapid growth and impressive development driven by the ability to bring in global top brands as customers during our time as investor in Attensi. This capital raise expands the investor universe with investors we know well from other Viking Venture portfolio companies and allows Attensi to continue its global expansion at increased pace.”
Established in 2012, Attensi has delivered gamified simulation training in more than 100 countries in 20 languages. Attensi solutions are used to simulate human interactions and work processes, including interpersonal ‘soft skills’, leadership training, use of IT-systems and any form of staff certification. Whether on mobile, desktop, or VR, Attensi’s gamified simulation approach enables organizations to upskill their people effectively, consistently, at scale, with all the data required to track impact on KPIs.
Attensi clients are corporate blue-chip companies in health care, pharmaceutical, financial services, professional services, retail, hospitality, manufacturing, shipping, offshore and transport, as well as public and third sectors. The company’s total revenue annual run-rate is currently $12m, and is headquartered in Oslo, Norway, with offices in London, UK, and Palo Alto, USA.
Pareto was engaged as Global Coordinator for the equity issue. GCA Altium is acting as the Global Financial Advisor to the company. Thommessen acted as the legal advisor in the transaction.
ENDS
Notes to editors:
About Attensi
Driven by the best of psychology, learning, and gaming, Attensi gamified simulation training engages your people with measurable impact on your KPIs. Whether on mobile, desktop, or VR, Attensi solutions empower people to learn new skills and behaviours in a fun, engaging way. The results enable organizations to excel in staff training, onboarding, and retention.
Attensi has delivered gamified simulation training in more than 100 countries, in 20 languages, and employs over 100 staff. Attensi is headquartered in Oslo, Norway, with offices in London, and Palo Alto, USA.
About Viking Venture
Viking Venture is the leading Nordic Software investor with more than NOK 3 billion under management. Since 2001, Viking Venture has invested in more than 50 Nordic companies with a particular focus on scaling Business-to-business (B2B) Software-as-a-Service (SaaS) companies. Viking Venture has been the lead investor of Attensi since 2018.
About Lugard Road Capital
Lugard Road Capital is a multi-billion-dollar global investment fund primarily focused on public and private companies in the Internet, software, consumer, and technology sectors.
About DX Ventures
DX Ventures is a venture capital fund backed by Delivery Hero. The fund’s mission is to support the next generation of founder-led companies that are disrupting some of the most rapidly changing industries around the world. The investment philosophy is centered on building long term partnerships with founders to provide support throughout the lifecycle and actively create value.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005063/en/
Contact information
Media:
Steve Maybury | steve@opr.co.uk | +44 (0)7985774743
Aranda Rahbarkouhi | aranda@opr.co.uk | +44 (0)7807009347
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
